PCR-based Approach for Determining the Genetic Risk Factors of Antipsychotic-Induced Metabolic Disorders-Reference-Cited by-同舟云学术

PCR-based Approach for Determining the Genetic Risk Factors of Antipsychotic-Induced Metabolic Disorders

Published:2022-05-15 Issue:1 Volume:2 Page:67-72
ISSN:2712-9179
Container-title:Personalized Psychiatry and Neurology
language:
Short-container-title:jour

Author:

Mironov K. O.¹,Gaponova I. I.,Korchagin V. I.¹,Esman A. S.¹,Dunaeva E. A.¹,Zhivotova V. A.¹,Dobrodeeva V. S.²,Shnayder N. A.³,Neznanov N. G.²,Nasyrova R. F.²

Affiliation:

1. Central Research Institute of Epidemiology

2. Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology

3. Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology; Shared Core Facilities Molecular and Cell Technologies, V. F. Voino-Yasenetsky Krasnoyarsk State Medical University

Abstract

The antipsychotic-induced metabolic disorders (AIMD) are common side effects during the treatment of schizophrenia. Single nucleotide polymorphisms in the genes associated with AIMD, in particular in the leptin and neuropeptide Y genes were explored. The aim of this study was to develop a real-time PCR technique for SNP allele discrimination and allele frequency estimation in the Russian population. A total of 9 real-time PCR tests for rs7799039, rs1137101, rs8179183, rs16147, rs6837793, rs11100494, rs1414334, rs3813929 and rs518147 SNPs were developed and examined using 106 DNA samples. The revealed allele frequencies did not show any statistically significant differences with ones for the Caucasian population from Ensembl data base. Thus, our results are in accordance with the allele frequencies for the studied populations and allow using published data on the risk alleles for the development of new diagnostics PCR kits for the complex diagnostics of AIMD.

Publisher

V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology

Reference13 articles.

1. Axelrod, E.V.; Mironov, K.O.; Dunaeva, E.A.; Shipulin, G.A. The comparison of three molecular genetic techniques for identifying major mutations in gene HFE related to development of inherent hemochromatosis. Clinical Laboratory Diagnosis, 2016, 61, 5, 316-320 (In Russ.), doi: 10.18821/0869-2084-2016-61-5-316-320.

2. Baranov, V.S. Genenic passport – the basic of individual predictive medicine. SPb.: N-L, 2009, 528 (In Russ.), ISBN 978-5-94869-084-1.

3. Dobrodeeva, V.S.; Shnayder, N.A.; Mironov, K.O.; Nasyrova, R.F. Pharmacogenetic markers of antipsychotic-induced weight gain: leptin and neuroepeptide Y. V.M. Behterev Rewiev of Psychiatry and Medical Psychology, 2021, 1, 3-10 (In Russ.), doi:10.31363/2313-7053-2021-1-3-10.

4. Nasyrova, R.F.; Neznanov, N.G. Clinical psychopharmacogenetics. SPb.: DEAN, 2019, 405 (InRuss.), ISBN 978-5-6043573-7-8.

5. Mironov, K.O.; Dunaeva, E.A.; Dribnokhodova, O.P.; Shipulin, G.A. Experience in using genetic analysis systems based on pyrosequencing technology. Spravocnik zaveduusego KDL, 2016, 5, 33–42 (In Russ.).